Key result
Tiapamil lowers systolic and diastolic blood pressure alongside fasting blood sugar in mild-to-moderate hypertension.
Why the study?
The antihypertensive and metabolic effects of tiapamil in mild to moderately hypertensive patients required evaluation in a long-term drug trial.
Tiapamil may reduce BP long-term without renal or hepatic impairment in small cohorts; leaves open comparative efficacy versus established agents.
Tiapamil, a new calcium antagonist, was evaluated for its antihypertensive and metabolic effects in a long-term (58 weeks) drug trial in 20 adult outpatient mild to moderately hypertensive subjects. Baseline systolic and diastolic blood pressure dropped after initiation of treatment and was significantly reduced after 4 weeks of treatment, further improving until the termination of the study. There was no impairment of renal and hepatic functions. Electrolytes, plasma aldosterone, plasma renin activity, as well as plasma lipids were not significantly altered during the course of therapy. Fasting blood sugar determinations and oral glucose tolerance test showed significant reductions from the baseline level as a result of the drug treatment. In conclusion, tiapamil is a metabolically safe and effective antihypertensive drug for long-term use.
No takes yet. Share an insight, caveat, or question.
Ding et al. (1990) studied Mild to moderate hypertension (n=20). Tiapamil vs. Baseline (before treatment) was evaluated on Systolic and diastolic blood pressure and metabolic parameters. Tiapamil treatment over 58 weeks significantly reduced systolic and diastolic blood pressure, as well as fasting blood sugar, in 20 adult outpatients with mild to moderate hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: